AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28380494 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated up-dosing regimen (0.1-0.3-0.5 mL at weekly intervals)
Number of subjects: 123
Study 28380494 — intervention group
Group type: COMPARATOR
Intervention: Conventional up-dosing regimen (0.05-0.1-0.2-0.3-0.4-0.5 mL at weekly intervals)
Number of subjects: 123
Study 28380494 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens (Accelerated and Conventional)
Number of subjects: 123
Study 25600249 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month aftercare programme (n = 25)
Number of subjects: 50
Study 25600249 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (n = 25)
Number of subjects: 50
Study 23490040 — intervention group
Group type: EXPERIMENTAL
Intervention: Double Kissing (DK) Crush
Number of subjects: 419
Study 23490040 — intervention group
Group type: COMPARATOR
Intervention: Culotte Stenting
Number of subjects: 419
Study 21888993 — intervention group
Group type: EXPERIMENTAL
Intervention: Dead Space Loading (DSL) 500 ml
Number of subjects: 11
Study 21888993 — intervention group
Group type: COMPARATOR
Intervention: Control (CTRL)
Number of subjects: 11
Study 19587069 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based recruitment through partnerships with local clinics
Number of subjects: 155
Study 19587069 — intervention group
Group type: COMPARATOR
Intervention: Academic site recruitment
Number of subjects: 155
Study 17033207 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant erythropoietin (rEPO)
Number of subjects: 30
Study 17033207 — intervention group
Group type: COMPARATOR
Intervention: Control group (no rEPO)
Number of subjects: 30
Study 14730255 — intervention group
Group type: EXPERIMENTAL
Intervention: Penumbral imaging using MRI
Number of subjects: 100
Study 14730255 — intervention group
Group type: EXPERIMENTAL
Intervention: DWI and PWI parameters
Number of subjects: 100
Study 14730255 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 100
Study 11114455 — intervention group
Group type: EXPERIMENTAL
Intervention: Television exposure to LSFA skill demonstrations
Number of subjects: 202
Study 11114455 — intervention group
Group type: COMPARATOR
Intervention: Control group (no TV exposure)
Number of subjects: 202
Study 9298135 — intervention group
Group type: EXPERIMENTAL
Intervention: Atopic Dermatitis (AD) group
Number of subjects: 129
Study 9298135 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergic Respiratory Disease (ARD) group
Number of subjects: 129
Study 9298135 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 129
Study 8117899 — intervention group
Group type: EXPERIMENTAL
Intervention: Weighted Least Squares (WLS)
Number of subjects: 0
Study 8117899 — intervention group
Group type: EXPERIMENTAL
Intervention: Iterative form of WLS
Number of subjects: 0
Study 8117899 — intervention group
Group type: EXPERIMENTAL
Intervention: Independence estimating equations
Number of subjects: 0
Study 3089467 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 ml iohexol
Number of subjects: 87
Study 3089467 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 ml iohexol
Number of subjects: 87
Study 3089467 — intervention group
Group type: COMPARATOR
Intervention: Creatinine clearance
Number of subjects: 87
Study 3089467 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast media
Number of subjects: 87
Study 3089467 — intervention group
Group type: EXPERIMENTAL
Intervention: Reproducibility of contrast clearance measurement
Number of subjects: 87
Study 31480979 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone administration
Number of subjects: 643
Study 31480979 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 643
Study 29713851 — intervention group
Group type: EXPERIMENTAL
Intervention: Yiqi Fumai lyophilized injection (5.2 g) with 250 ml 5% glucose/sodium injection for 7 days
Number of subjects: 666
Study 29713851 — intervention group
Group type: COMPARATOR
Intervention: Standardized western medications (control group) for 7 days
Number of subjects: 666
Study 26711719 — intervention group
Group type: COMPARATOR
Intervention: M‐Ex‐M (morning and evening metformin doses, with exercise)
Number of subjects: 10
Study 26711719 — intervention group
Group type: EXPERIMENTAL
Intervention: M‐Ex (exercise with evening metformin dose only)
Number of subjects: 10
Study 26711719 — intervention group
Group type: EXPERIMENTAL
Intervention: Ex‐M (morning metformin dose only, with exercise)
Number of subjects: 10
Study 26711719 — intervention group
Group type: COMPARATOR
Intervention: M‐M (morning and evening metformin doses, without exercise)
Number of subjects: 10
Study 26711719 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise conditions (M‐Ex‐M, M‐Ex, Ex‐M)
Number of subjects: 10
Study 24447190 — intervention group
Group type: EXPERIMENTAL
Intervention: Disgust condition
Number of subjects: 80
Study 24447190 — intervention group
Group type: EXPERIMENTAL
Intervention: Trait disgust
Number of subjects: 80
Study 24447190 — intervention group
Group type: EXPERIMENTAL
Intervention: State disgust
Number of subjects: 80
Study 24447190 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 80
Study 21822142 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest CT interpretation lecture
Number of subjects: 58
Study 21822142 — intervention group
Group type: COMPARATOR
Intervention: No lecture (Control)
Number of subjects: 58
Study 19931965 — intervention group
Group type: EXPERIMENTAL
Intervention: Left nostril for NTI
Number of subjects: 54
Study 19931965 — intervention group
Group type: COMPARATOR
Intervention: Right nostril for NTI
Number of subjects: 54
Study 17963264 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX4 until progression (arm A)
Number of subjects: 37
Study 17963264 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX7 for 6 cycles, maintenance without oxaliplatin for 12 cycles, and reintroduction of FOLFOX7 (arm B)
Number of subjects: 37
Study 17963264 — intervention group
Group type: COMPARATOR
Intervention: Younger patients (<=75 years)
Number of subjects: 37
Study 15349656 — intervention group
Group type: EXPERIMENTAL
Intervention: rhEPO 6000IU subcutaneously for 3 times a week and Ferrost sulfatis Et vitamini‐medtech 1 tablet per day for 12 days
Number of subjects: 31
Study 15349656 — intervention group
Group type: COMPARATOR
Intervention: Ferrost sulfatis Et vitamini‐medtech (same dose as experimental group)
Number of subjects: 31
Study 10647546 — intervention group
Group type: EXPERIMENTAL
Intervention: Push frequency at 140% of freely chosen frequency (FCF)
Number of subjects: 8
Study 10647546 — intervention group
Group type: COMPARATOR
Intervention: Push frequency at 60% FCF
Number of subjects: 8
Study 10647546 — intervention group
Group type: EXPERIMENTAL
Intervention: Push frequency at freely chosen frequency (FCF)
Number of subjects: 8
Study 10647546 — intervention group
Group type: EXPERIMENTAL
Intervention: Push frequency at 100% FCF
Number of subjects: 8
Study 10647546 — intervention group
Group type: EXPERIMENTAL
Intervention: Push frequency at varying percentages of FCF (60%, 80%, 120%, 140%)
Number of subjects: 8
Study 10647546 — intervention group
Group type: EXPERIMENTAL
Intervention: Push frequency at varying percentages of FCF
Number of subjects: 8
Study 9028716 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. 1,25‐dihydroxyvitamin D3
Number of subjects: 12
Study 9028716 — intervention group
Group type: EXPERIMENTAL
Intervention: oral Etalpha (0.25 microgram)
Number of subjects: 12
Study 9028716 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. and oral 1,25‐dihydroxyvitamin D3
Number of subjects: 12
Study 9028716 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,25‐dihydroxyvitamin D3 and insulin
Number of subjects: 12
Study 8333761 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse oximetry
Number of subjects: 20
Study 3591258 — intervention group
Group type: EXPERIMENTAL
Intervention: Heating of inspired humidified gases
Number of subjects: 111
Study 3591258 — intervention group
Group type: EXPERIMENTAL
Intervention: Heating mattress
Number of subjects: 111
Study 3591258 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat supply (combined measures)
Number of subjects: 111
Study 3591258 — intervention group
Group type: COMPARATOR
Intervention: Unwarmed control
Number of subjects: 111
Study 29958906 — intervention group
Group type: EXPERIMENTAL
Intervention: ADSTEP
Number of subjects: 40
Study 27735028 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-calorie diet (LC)
Number of subjects: 114
Study 27735028 — intervention group
Group type: EXPERIMENTAL
Intervention: Isocaloric diet with 500 mg of metformin twice a day (IM)
Number of subjects: 114
Study 27735028 — intervention group
Group type: EXPERIMENTAL
Intervention: Isocaloric diet with 120 mg of orlistat three times a day (IO)
Number of subjects: 114
Study 25474455 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryosurgery and 5-fluorouracil cream 0.5%
Number of subjects: 60
Study 25474455 — intervention group
Group type: COMPARATOR
Intervention: Cryosurgery alone
Number of subjects: 60
Study 22030098 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-chain triglycerides (MCT) supplementation prior to exercise
Number of subjects: 11
Study 22030098 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate (CHO) supplementation prior to exercise
Number of subjects: 11
Study 20512584 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal strength training (MST) - 4 x 4 repetitions of unilateral dynamic leg press and plantar flexion, 5 days a week for 3 weeks.
Number of subjects: 14
Study 20512584 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) - received 'today's treatment' without additional strength training.
Number of subjects: 14
Study 18417236 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrocutaneous stimulation over the sural nerve
Number of subjects: 0
Study 18417236 — intervention group
Group type: EXPERIMENTAL
Intervention: Different methods of scoring NFR magnitude
Number of subjects: 0
Study 15916998 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 20-min walk (one bout)
Number of subjects: 48
Study 15916998 — intervention group
Group type: EXPERIMENTAL
Intervention: Two 10-min walks (accumulated bouts)
Number of subjects: 48
Study 15916998 — intervention group
Group type: COMPARATOR
Intervention: No training (control)
Number of subjects: 48
Study 12660502 — intervention group
Group type: EXPERIMENTAL
Intervention: sirolimus (study group, n=15)
Number of subjects: 33
Study 12660502 — intervention group
Group type: COMPARATOR
Intervention: tacrolimus and mycophenolate mofetil (control group, n=18)
Number of subjects: 33
Study 10729758 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound imaging of Bartholin's cysts
Number of subjects: 36
Study 10729758 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up US examination after surgery
Number of subjects: 36
Study 8861991 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable insulin pump (IIP)
Number of subjects: 121
Study 8861991 — intervention group
Group type: COMPARATOR
Intervention: Multiple daily insulin (MDI)
Number of subjects: 121
Study 1735400 — intervention group
Group type: EXPERIMENTAL
Intervention: hyperbaric Niphanoid tetracaine (6 or 10 mg)
Number of subjects: 137
Study 1735400 — intervention group
Group type: EXPERIMENTAL
Intervention: hyperbaric bupivacaine (6 mg)
Number of subjects: 137
Study 1735400 — intervention group
Group type: EXPERIMENTAL
Intervention: hyperbaric Niphanoid tetracaine (6 mg) with adrenaline
Number of subjects: 137
Study 1735400 — intervention group
Group type: EXPERIMENTAL
Intervention: hyperbaric bupivacaine (6 mg) with adrenaline
Number of subjects: 137
Study 1735400 — intervention group
Group type: EXPERIMENTAL
Intervention: light intravenous supplementation with low doses of fentanyl and/or thiopentone
Number of subjects: 137
Study 6704006 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabeculectomy
Number of subjects: 71
Study 6704006 — intervention group
Group type: COMPARATOR
Intervention: Thermosclerostomy
Number of subjects: 71
Study 6704006 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 71
Study 30732192 — intervention group
Group type: EXPERIMENTAL
Intervention: Furazolidone-based quadruple therapy (FZD) for 14 days with esomeprazole, bismuth potassium citrate, and amoxicillin
Number of subjects: 185
Study 30732192 — intervention group
Group type: COMPARATOR
Intervention: Clarithromycin-based quadruple therapy (CLA) for 14 days with esomeprazole, bismuth potassium citrate, and amoxicillin
Number of subjects: 185
Study 29932518 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher protein (HP) infant formula
Number of subjects: 1090
Study 27422252 — intervention group
Group type: EXPERIMENTAL
Intervention: 50th percentile with incentives (n = 100)
Number of subjects: 286
Study 27422252 — intervention group
Group type: EXPERIMENTAL
Intervention: 75th percentile with incentives (n = 64)
Number of subjects: 286
Study 27422252 — intervention group
Group type: EXPERIMENTAL
Intervention: 50th percentile without incentives (n = 80)
Number of subjects: 286
Study 27422252 — intervention group
Group type: COMPARATOR
Intervention: 75th percentile without incentives (n = 44)
Number of subjects: 286
Study 24196279 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity modulated radiotherapy (IMRT) with doses of 73.9 Gy (n = 41) and 76.2 Gy (n = 109) delivered in 32 and 33 fractions, respectively.
Number of subjects: 150
Study 24196279 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity modulated radiotherapy (IMRT) with doses of 73.9 Gy and 76.2 Gy.
Number of subjects: 150
Study 22108449 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretta procedure
Number of subjects: 22
Study 22108449 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (esophageal smooth muscle relaxant)
Number of subjects: 22
Study 22108449 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 22
Study 19915736 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflavone (100 mg/day for 4 months)
Number of subjects: 38
Study 19915736 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 17846017 — intervention group
Group type: COMPARATOR
Intervention: ABVD alone
Number of subjects: 33
Study 17846017 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Number of subjects: 33
Study 14639137 — intervention group
Group type: EXPERIMENTAL
Intervention: Epsilon-aminocaproic acid (epsilon-ACA) prior to skin incision (bolus 150 mg/kg, followed by an infusion at 15 mg x kg(‐1) x hr(‐1))
Number of subjects: 90
Study 14639137 — intervention group
Group type: EXPERIMENTAL
Intervention: Epsilon-aminocaproic acid (epsilon-ACA) after heparin (same doses)
Number of subjects: 90
Study 14639137 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 12666969 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonicare toothbrush in active mode ('on')
Number of subjects: 20
Study 12666969 — intervention group
Group type: COMPARATOR
Intervention: Sonicare toothbrush in manual mode ('off')
Number of subjects: 20
Study 8865950 — intervention group
Group type: EXPERIMENTAL
Intervention: High school alcohol misuse prevention program
Number of subjects: 1041
Study 1624202 — intervention group
Group type: EXPERIMENTAL
Intervention: Concept 45 degrees toothbrush
Number of subjects: 36
Study 1624202 — intervention group
Group type: COMPARATOR
Intervention: Control toothbrush
Number of subjects: 36
Study 6528617 — intervention group
Group type: EXPERIMENTAL
Intervention: Substitution of antithrombin III (AT III)
Number of subjects: 16
Study 6528617 — intervention group
Group type: COMPARATOR
Intervention: No substitution of antithrombin III (Control group)
Number of subjects: 16
Study 31377477 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib (1500 mg/day)
Number of subjects: 455
Study 31377477 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab (common dose)
Number of subjects: 455
Study 31377477 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib (1000 mg/day) plus Trastuzumab
Number of subjects: 455
Study 31377477 — intervention group
Group type: EXPERIMENTAL
Intervention: pCR (pathologic complete response)
Number of subjects: 455
Study 28032343 — intervention group
Group type: EXPERIMENTAL
Intervention: High-density surface electromyography tracking method
Number of subjects: 17
Study 28032343 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training (cycling)
Number of subjects: 17
Study 25581856 — intervention group
Group type: EXPERIMENTAL
Intervention: OND OSF 8 mg (ZUPLENZ)
Number of subjects: 114
Study 25581856 — intervention group
Group type: COMPARATOR
Intervention: OND ODT 8 mg (ZOFRAN)
Number of subjects: 114
Study 23511031 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (500 mg twice daily)
Number of subjects: 33
Study 23511031 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 23511031 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 33
Study 21874215 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined aerobic endurance and resistance muscle training
Number of subjects: 60
Study 21874215 — intervention group
Group type: COMPARATOR
Intervention: Aerobic endurance training
Number of subjects: 60
Study 19833273 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine (5 mg) with 2-minute sitting position after injection
Number of subjects: 180
Study 19833273 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine (5 mg) with 5-minute sitting position after injection
Number of subjects: 180
Study 19833273 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine (5 mg) with 10-minute sitting position after injection
Number of subjects: 180
Study 16720940 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory muscle strength training technique
Number of subjects: 28
Study 16720940 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory muscle strength training
Number of subjects: 28
Study 16533192 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin B
Number of subjects: 20
Study 16533192 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 10371004 — intervention group
Group type: EXPERIMENTAL
Intervention: Stabilisation appliance
Number of subjects: 60
Study 10371004 — intervention group
Group type: COMPARATOR
Intervention: Control appliance
Number of subjects: 60
Study 10371004 — intervention group
Group type: EXPERIMENTAL
Intervention: Background variable - Male sex
Number of subjects: 60
Study 10371004 — intervention group
Group type: EXPERIMENTAL
Intervention: Background variable - Severe or very severe TMJ pain
Number of subjects: 60
Study 8879466 — intervention group
Group type: EXPERIMENTAL
Intervention: 25‐mg CMI slow infusion
Number of subjects: 27
Study 8879466 — intervention group
Group type: COMPARATOR
Intervention: 25‐mg CMI tablet
Number of subjects: 27
Study 2000648 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression antiembolism stocking (T.E.D.)
Number of subjects: 149
Study 2000648 — intervention group
Group type: COMPARATOR
Intervention: Ace-bandage
Number of subjects: 149
Study 6838322 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine hydrochloride
Number of subjects: 6
Study 6838322 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine hydrochloride
Number of subjects: 6
Study 6838322 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 6
Study 31083777 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal high-flow (NHF) therapy at 45 L/min
Number of subjects: 24
Study 31083777 — intervention group
Group type: COMPARATOR
Intervention: Non-invasive ventilation (NIV) at 15/4 cm H2O
Number of subjects: 24
Study 31083777 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal high-flow (NHF) therapy
Number of subjects: 24
Study 29600719 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-Rich Plasma (PRP) injection
Number of subjects: 80
Study 29600719 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid injection
Number of subjects: 80
Study 27551113 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective neck dissection in conjunction with primary surgery
Number of subjects: 0
Study 27551113 — intervention group
Group type: COMPARATOR
Intervention: Primary surgery alone
Number of subjects: 0
Study 25349301 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine 1,000 mg/m² and carboplatin AUC 2 plus iniparib 5.6 mg/kg (GCI)
Number of subjects: 519
Study 25349301 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine 1,000 mg/m² and carboplatin AUC 2 (GC)
Number of subjects: 519
Study 25349301 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine 1,000 mg/m² and carboplatin AUC 2 plus iniparib 5.6 mg/kg (GCI) in second-/third-line treatment
Number of subjects: 519
Study 22293533 — intervention group
Group type: EXPERIMENTAL
Intervention: PHX1766 800 mg twice daily
Number of subjects: 70
Study 22293533 — intervention group
Group type: COMPARATOR
Intervention: PHX1766 (various doses: 50 mg once daily - 1000 mg once daily, 250 mg twice daily)
Number of subjects: 70
Study 22293533 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 20415623 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine 0.05%
Number of subjects: 58
Study 20415623 — intervention group
Group type: COMPARATOR
Intervention: Artificial tears
Number of subjects: 58
Study 18567089 — intervention group
Group type: EXPERIMENTAL
Intervention: Da Cheng Qi Decoction enema and external use of Glauber's salt, once a day for 7 days.
Number of subjects: 80
Study 18567089 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (NS) enema.
Number of subjects: 80
Study 15929749 — intervention group
Group type: COMPARATOR
Intervention: Proton pump inhibitors (PPIs)
Number of subjects: 8
Study 15929749 — intervention group
Group type: EXPERIMENTAL
Intervention: PPI test
Number of subjects: 8
Study 12739240 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid treatment
Number of subjects: 36
Study 12739240 — intervention group
Group type: COMPARATOR
Intervention: Nonsteroid treatment
Number of subjects: 36
Study 12739240 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid treatment in cases with persistent canal paresis
Number of subjects: 36
Study 12739240 — intervention group
Group type: COMPARATOR
Intervention: Nonsteroid treatment in cases with persistent canal paresis
Number of subjects: 36
Study 10595814 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg) prophylaxis (500 mg/kg/d loading from day -6 to -1 and then 100 mg/kg every 3 days from day 3 to 90)
Number of subjects: 241
Study 10595814 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg) prophylaxis
Number of subjects: 241